FDA Inspection 1094312 — Pierre Fabre Medicament

Pierre Fabre Medicament — FEI 3002807889

The FDA completed an inspection of Pierre Fabre Medicament on Jul 13, 2018 in Gaillac. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI)
End Date
Jul 13, 2018
Fiscal Year
2018
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Gaillac (France)

Additional Details

Mutual Recognition Agreement (MRA)